Certara, a global biosimulation technology-enabled drug development and drug safety consulting company, has promoted Amin Rostami, Pharm.D., Ph.D., to senior vice president of R&D and chief scientific officer at Certara. Professor Rostami previously was co-founder and vice president of R&D for Certara’s Simcyp Business Unit.
As senior vice president of R&D and chief scientific officer, Rostami will lead Certara’s scientific brain trust, which includes almost 100 staff members with Ph.D.s or M.D.s, ensuring that the latest science is incorporated into all of the company’s products and activities. He also will partner with Certara’s president of technology, and the heads of its business units and corporate sales and marketing teams, to maximize the company’s scientific assets.
In addition to his work with Certara, Rostami is a professor of systems pharmacology at the University of Manchester, England. In this capacity, he acts as an interface between academia and industry helping to show modeling and simulation applications and demonstrating how they can create the biological data required as input into modeling tools that will positively impact the drug development process, and ultimately patient care.
Professor Rostami has more than 25 years’ experience in drug research and 15 years’ experience in leadership positions. He has been invited to speak at more than 140 international meetings, and is routinely asked by regulatory agencies, including the FDA and EMA, to support and advise on the development of industry guidance on biosimulation.